摘要
目的比较冠心病者以阿托伐他汀、瑞舒伐他汀治疗的疗效差异。方法本次研究对象选取我院于2015年2月~2016年4月期间收治的100例冠心病者,将患者以随机排列表法分为对比、观察两组,其中对比组48例(用药阿托伐他汀)、观察组52例(用药瑞舒伐他汀)。比较治疗前后患者血脂指标[胆固醇(TC)、低密度脂蛋白(LDL-C)]含量以及超敏C反应蛋白(hs-CRP)、同型半胱氨酸(Hcy)水平变化情况,统计治疗期间用药所致不良事件。结果用药后观察组hs-CRP、Hcy及血脂指标水平降低效果优于对比组(P<0.05)。结论阿托伐他汀、瑞舒伐他汀临床用于冠心病治疗均良好降脂效果,且后者降脂效果优于前者,两种药物用于冠心病治疗不良反应少、安全性高。
Objective To compare the difference of efficacy of atorvastatin statin therapy for coronary heart disease. Methods 100 patients with coronary heart disease who were admitted in our hospital from February 2015 to April 2016 were selected, and the patients were divided into two groups by random order table method. Among them, 48 cases of comparison group were given to atorvastatin observation group and 52 cases were given to risuvastatin. Before and after treatment, the blood lipid index [cholesterol （TC）, low density lipoprotein （LDL-C）] content and levels of hypersensitive c-reactive protein （hs-CRP）, levels of homocysteine （Hcy） and statistical treatment caused by drug adverse events in all patients of two groups with were compared. Results The effect of hs-CRP, Hcy and blood lipid index in the observation group was better than that of the comparison group（P 〈 0.05）. Conclusion The clinical application of atorvastatin and rishuvastatin in the treatment of coronary heart disease has good lipid lowering effect, And rishuvastatin is better than atorvastatin, two drugs are used to treat adverse reactions with low safety and high safety.
出处
《中国医药科学》
2017年第19期74-76,共3页
China Medicine And Pharmacy
关键词
降脂
冠心病
瑞舒伐他汀
阿托伐他汀
Reducing lipid
Coronary heart disease
Resuvastatin
Atorvastatin
